SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
SEC Accession No. 0001193125-11-063548
Filing Date
2011-03-11
Accepted
2011-03-11 13:17:14
Documents
7
Period of Report
2010-12-31
Filing Date Changed
2011-03-11

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d10k.htm 10-K 1180878
2 AMENDED AND RESTATED LICENSE AGREEMENT dex1027.htm EX-10.27 109921
3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM dex231.htm EX-23.1 2363
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER dex311.htm EX-31.1 8470
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER dex312.htm EX-31.2 8463
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER dex321.htm EX-32.1 8424
7 GRAPHIC g152162g49h97.jpg GRAPHIC 44841
  Complete submission text file 0001193125-11-063548.txt   1381482
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33415 | Film No.: 11681200
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1